Lara Zakaria, PharmD, introduced the topic of pharmaconutrition, urging pharmacists to integrate food, lifestyle, and gut health into patient care through evidence-based, practical interventions.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

Gustavo Alva, MD, a board-certified psychiatrist, discusses the importance of mental health awareness among both pharmacists and patients.

By closing the gap on patients recommended lipid-lowering therapies who do not receive them, researchers say that thousands of cardiovascular events could be prevented and billions of dollars would be saved.

mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

New research highlights the lower infection risk with zanubrutinib compared to venetoclax in CLL/SLL treatment, offering safer options for patients.

Discover how vitamin D supplementation may reduce Autism Spectrum Disorder symptoms and improve overall functioning in children with ASD.

Though cholesterol-lowering guidance often touts the achievement of very low levels of low-density lipoprotein (LDL) cholesterol, emerging research demonstrates possible safety risks.

Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.

The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.

FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.

Packed with CE sessions, interactive learning, expert insights, and a vibrant expo floor, McKesson ideaShare 2025 aims to equip independent pharmacists with the tools and strategies to elevate patient care and drive pharmacy innovation.

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

The conference offers immersive, peer-driven education tracks designed to help independent pharmacies innovate, adapt, and thrive in a changing health care landscape.

New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.

Real-world studies reveal GLP-1 medications like semaglutide and tirzepatide yield less weight loss than clinical trials, highlighting treatment discontinuation challenges.

New research reveals that extracellular vesicles enhance intranasal flu vaccines, boosting mucosal immunity and offering broader protection against diverse strains.

The FDA is warning of rare severe itching after stopping long-term use of popular allergy medications cetirizine and levocetirizine, urging patient education.

AI is revolutionizing pharmacovigilance by enhancing data analysis, improving patient safety, and enabling proactive risk management in drug monitoring.

The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.

The lawsuit alleges that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. violated the law when issuing new guidance for COVID-19 vaccination.